Company Long-Term Loans and Borrowings: Akero Therapeutics Inc (AKRO)

Public company logo of Akero Therapeutics Inc (AKRO)

Akero Therapeutics (AKRO) develops independently of macro cycles, relying instead on clinical trial results. The dynamics of the corporation's long-term credits and loans demonstrate its current financial status, where 0.00 characterizes this valuation parameter. Future success is based on low-cost molecule synthesis coupled with high sales margins. Meanwhile, drug delivery requires an expensive cold chain to maintain efficacy.

AKRO Akero Therapeutics Company Long-Term Debts (07/04/2022 - 12/20/2025)

Summary analytical data breakdowns for Akero Therapeutics Inc (AKRO)

- market price and analyst price targets:
Stock Price akerotx.com|AKRO - Price Target Chart
- company stock exchange capitalization indicators:
Market Value Akero Therapeutics|AKRO - Total Company Value
- book capitalization information:
Accounting Value per Share Akero Therapeutics|AKRO - Book Capitalization|Market Capitalization to Book Value Ratio akerotx.com|AKRO - Cumulative Company Assets
- debt level and financial liquidity data:
All Debt to Shareholders' Equity Ratio Akero Therapeutics|AKRO - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Akero Corp|AKRO - Company Aggregate Debts|Debts to Book Value Akero Therapeutics|AKRO - Company Long-Term Liabilities|Amount of Current Liabilities Akero Therapeutics|Quick Ratio akerotx.com
- earnings and multiples data:
AKRO - Net Profit
Summary company analytics:Akero Therapeutics
Brand item of Akero Therapeutics

Akero Therapeutics' focus on R&D and outsourced manufacturing makes the company dependent on external capital to fund its development. An analysis of the company's long-term debt structure with a value of 0.00 allows for an assessment of multi-year obligations and the risk of balance sheet overheating, determining the extent to which debt financing accelerates growth without exerting critical pressure on the market value of the shares.

Competitor analysis for Akero Therapeutics

Company Long-Term Debts ascendispharma.com ASND|MDGL - Company Long-Term Debt|Company Long-Term Loans and Borrowings CORT (Corcept Therapeutics Inc.)|Rhythm Pharmaceuticals Inc (RYTM) - Company Long-Term Debt|Company Long-Term Liabilities Metsera Therapeutics|MLTX (MoonLake Immunotherapeutics) - Company Long-Term Debts|Company Long-Term Debts crinetics.com|Company Long-Term Liabilities NAMS (NewAmsterdam Pharma Company N.V.)|SLNO (Soleno Therapeutics Inc) - Company Long-Term Loans and Borrowings|Company Long-Term Debt Amicus Pharma FOLD|ETNB - Company Long-Term Liabilities|Agios Pharmaceuticals - Company Long-Term Debts|Long-Term Debt structuretx.com|MDXG (MiMedx) - Company Long-Term Liabilities|RZLT: Amount of Long-Term Liabilities|LXRX (Lexicon Pharma) - Company Long-Term Debts|Company Long-Term Debts MBX Corp|Company Long-Term Debts ALT|Company Long-Term Debt AARD (aardvarktherapeutics.com)|Company Long-Term Debt Sagimet Biosciences Inc. SGMT|BioAge Labs (BIOA) - Long-Term Debt|BMEA - Company Long-Term Debt|QNCX: Company Long-Term Debt|GUTS: Company Long-Term Debts|VTVT - Long-Term Debt Volume|Company Long-Term Debt Agape ATP Corp|Pluri Inc (PLUR) - Long-Term Debt Volume|Company Long-Term Debt Synlogic, Inc. (SYBX)|Company Long-Term Liabilities Lipocine Corporation LPCN|Company Long-Term Debts MTNB (Matinas BioPharma Holdings)|Company Long-Term Debts Spruce Biosciences Inc. SPRB|GLTO - Company Long-Term Debt|CTCX - Company Long-Term Debts|LUMO: Company Long-Term Debts|Long-Term Debt Organovo Corp (ONVO)|Company Long-Term Debt Radius Recycling, Inc.